398 related articles for article (PubMed ID: 32952855)
1. Mesenchymal stromal cells as potential immunomodulatory players in severe acute respiratory distress syndrome induced by SARS-CoV-2 infection.
Mallis P; Michalopoulos E; Chatzistamatiou T; Stavropoulos-Giokas C
World J Stem Cells; 2020 Aug; 12(8):731-751. PubMed ID: 32952855
[TBL] [Abstract][Full Text] [Related]
2. Exploring the Immunomodulatory Aspect of Mesenchymal Stem Cells for Treatment of Severe Coronavirus Disease 19.
Chaudhary JK; Saini D; Chaudhary PK; Maurya A; Verma GK; Gupta AK; Roshan R; Vats TK; Garg N; Yadav D; Kant N; Meena AK; Mirza-Shariff AA
Cells; 2022 Jul; 11(14):. PubMed ID: 35883618
[TBL] [Abstract][Full Text] [Related]
3. Disruption of CCR5 signaling to treat COVID-19-associated cytokine storm: Case series of four critically ill patients treated with leronlimab.
Agresti N; Lalezari JP; Amodeo PP; Mody K; Mosher SF; Seethamraju H; Kelly SA; Pourhassan NZ; Sudduth CD; Bovinet C; ElSharkawi AE; Patterson BK; Stephen R; Sacha JB; Wu HL; Gross SA; Dhody K
J Transl Autoimmun; 2021; 4():100083. PubMed ID: 33521616
[TBL] [Abstract][Full Text] [Related]
4. Expanded Umbilical Cord Mesenchymal Stem Cells (UC-MSCs) as a Therapeutic Strategy in Managing Critically Ill COVID-19 Patients: The Case for Compassionate Use.
Atluri S; Manchikanti L; Hirsch JA
Pain Physician; 2020 Mar; 23(2):E71-E83. PubMed ID: 32214286
[TBL] [Abstract][Full Text] [Related]
5. Mesenchymal stromal cell delivery as a potential therapeutic strategy against COVID-19: Promising evidence from
Mallis P; Chatzistamatiou T; Dimou Z; Sarri EF; Georgiou E; Salagianni M; Triantafyllia V; Andreakos E; Stavropoulos-Giokas C; Michalopoulos E
World J Biol Chem; 2022 Mar; 13(2):47-65. PubMed ID: 35432769
[TBL] [Abstract][Full Text] [Related]
6. Mesenchymal stem cells derived from perinatal tissues for treatment of critically ill COVID-19-induced ARDS patients: a case series.
Hashemian SR; Aliannejad R; Zarrabi M; Soleimani M; Vosough M; Hosseini SE; Hossieni H; Keshel SH; Naderpour Z; Hajizadeh-Saffar E; Shajareh E; Jamaati H; Soufi-Zomorrod M; Khavandgar N; Alemi H; Karimi A; Pak N; Rouzbahani NH; Nouri M; Sorouri M; Kashani L; Madani H; Aghdami N; Vasei M; Baharvand H
Stem Cell Res Ther; 2021 Jan; 12(1):91. PubMed ID: 33514427
[TBL] [Abstract][Full Text] [Related]
7. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
[TBL] [Abstract][Full Text] [Related]
8. Double-blind, randomized, controlled, trial to assess the efficacy of allogenic mesenchymal stromal cells in patients with acute respiratory distress syndrome due to COVID-19 (COVID-AT): A structured summary of a study protocol for a randomised controlled trial.
Payares-Herrera C; Martínez-Muñoz ME; Vallhonrat IL; de Molina RM; Torres MP; Trisan A; de Diego IS; Alonso R; Zafra R; Donaire T; Sánchez R; Rubio JJ; Duarte Palomino RF; Solá CA
Trials; 2021 Jan; 22(1):9. PubMed ID: 33407777
[TBL] [Abstract][Full Text] [Related]
9. Umbilical Cord-derived Mesenchymal Stem Cells for COVID-19 Patients with Acute Respiratory Distress Syndrome (ARDS).
Lanzoni G; Linetsky E; Correa D; Alvarez RA; Marttos A; Hirani K; Cayetano SM; Castro JG; Paidas MJ; Efantis Potter J; Xu X; Glassberg M; Tan J; Patel AN; Goldstein B; Kenyon NS; Baidal D; Alejandro R; Vianna R; Ruiz P; Caplan AI; Ricordi C
CellR4 Repair Replace Regen Reprogram; 2020; 8():. PubMed ID: 34164564
[TBL] [Abstract][Full Text] [Related]
10. Systematic review and meta-analysis of cell therapy for COVID-19: global clinical trial landscape, published safety/efficacy outcomes, cell product manufacturing and clinical delivery.
Couto PS; Al-Arawe N; Filgueiras IS; Fonseca DLM; Hinterseher I; Catar RA; Chinnadurai R; Bersenev A; Cabral-Marques O; Moll G; Verter F
Front Immunol; 2023; 14():1200180. PubMed ID: 37415976
[TBL] [Abstract][Full Text] [Related]
11. Mesenchymal Stromal Cells for Enhancing Hematopoietic Engraftment and Treatment of Graft-Versus-Host Disease, Hemorrhages and Acute Respiratory Distress Syndrome.
Ringdén O; Moll G; Gustafsson B; Sadeghi B
Front Immunol; 2022; 13():839844. PubMed ID: 35371003
[TBL] [Abstract][Full Text] [Related]
12. Expediting Molecular Translational Approach of Mesenchymal Stem Cells in COVID-19 Treatment.
Balaji Easwaran V; Satarker S; V Gujaran T; John J; Veedu AP; George KT; Purayil DK; Beegum F; Mathew A; Vibhavari R; Chaudhari SS; Pai KSR
Curr Stem Cell Res Ther; 2023; 18(5):653-675. PubMed ID: 36424799
[TBL] [Abstract][Full Text] [Related]
13. Systematic review and meta-analysis of mesenchymal stromal/stem cells as strategical means for the treatment of COVID-19.
Taufiq H; Shaik Fakiruddin K; Muzaffar U; Lim MN; Rusli S; Kamaluddin NR; Esa E; Abdullah S
Ther Adv Respir Dis; 2023; 17():17534666231158276. PubMed ID: 37128999
[TBL] [Abstract][Full Text] [Related]
14. Inflammatory Cytokine: IL-17A Signaling Pathway in Patients Present with COVID-19 and Current Treatment Strategy.
Shibabaw T
J Inflamm Res; 2020; 13():673-680. PubMed ID: 33116747
[TBL] [Abstract][Full Text] [Related]
15. Cytokine storm and leukocyte changes in mild versus severe SARS-CoV-2 infection: Review of 3939 COVID-19 patients in China and emerging pathogenesis and therapy concepts.
Wang J; Jiang M; Chen X; Montaner LJ
J Leukoc Biol; 2020 Jul; 108(1):17-41. PubMed ID: 32534467
[TBL] [Abstract][Full Text] [Related]
16. Facing the Challenges in the COVID-19 Pandemic Era: From Standard Treatments to the Umbilical Cord-Derived Mesenchymal Stromal Cells as a New Therapeutic Strategy.
Russo E; Corrao S; Di Gaudio F; Alberti G; Caprnda M; Kubatka P; Kruzliak P; Miceli V; Conaldi PG; Borlongan CV; La Rocca G
Cells; 2023 Jun; 12(12):. PubMed ID: 37371134
[TBL] [Abstract][Full Text] [Related]
17. Tocilizumab in SARS-CoV-2 Patients with the Syndrome of Cytokine Storm: A Narrative Review.
Kulanthaivel S; Kaliberdenko VB; Balasundaram K; Shterenshis MV; Scarpellini E; Abenavoli L
Rev Recent Clin Trials; 2021; 16(2):138-145. PubMed ID: 32940187
[TBL] [Abstract][Full Text] [Related]
18. Critical Determinants of Cytokine Storm and Type I Interferon Response in COVID-19 Pathogenesis.
Ramasamy S; Subbian S
Clin Microbiol Rev; 2021 Jun; 34(3):. PubMed ID: 33980688
[TBL] [Abstract][Full Text] [Related]
19. Mesenchymal stem cells as living anti-inflammatory therapy for COVID-19 related acute respiratory distress syndrome.
Lin F; Ichim TE; Pingle S; Jones LD; Kesari S; Ashili S
World J Stem Cells; 2020 Oct; 12(10):1067-1079. PubMed ID: 33178392
[TBL] [Abstract][Full Text] [Related]
20. Perspectives on mesenchymal stem/progenitor cells and their derivates as potential therapies for lung damage caused by COVID-19.
Klimczak A
World J Stem Cells; 2020 Sep; 12(9):1013-1022. PubMed ID: 33033561
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
